Quality of conventional release verapamil prescription in patients with arterial hypertension

Revista de calidad asistencial : organo de la Sociedad Española de Calidad Asistencial
Jorge Enrique Machado-AlbaManuel Enrique Machado-Duque

Abstract

To identify patients who were being treated for hypertension with conventional release verapamil (CRV), and to notify the professional responsible for their health care on cardiovascular risk to which they are exposed and achieve a reduction in the number of patients who are treated with this drug. A quasi-experimental prospective before and after study without a control group was conducted on 7289 patients diagnosed with hypertension who were on treatment with CRV, between October 1, 2012 and December 31, 2012 in 8 Colombian cities, collected from a database for dispensing medicines. Socio-demographic and pharmacological variables were evaluated. A total of 108 educational interventions were performed on those responsible for their health care, and evaluated within three months with the proportion of suspension of the prescriptions of CRV being evaluated. Multivariate analysis was performed using SPSS 22.0. The mean age of patients was 67.9±11.8 years (range: 26-96 years), of which 70.6% were men. Withdrawal of treatment with CRV was achieved in a total of 1922 patients (26.3% of users), distributed as follows: 1160 (60.4%) were the presentation of 120mg, while 762 (39.6%) the 80mg. The variable being treated in the city of Me...Continue Reading

References

Nov 1, 1995·Journal of the American Geriatrics Society·M PahorR J Havlik
Aug 23, 1995·JAMA : the Journal of the American Medical Association·B M PsatyP W Wahl
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Michael A Weber
Jan 27, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Stefano TaddeiLorenzo Ghiadoni
Apr 21, 2011·JAMA : the Journal of the American Medical Association·Dario Giugliano, Katherine Esposito
Jul 12, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Suresh Samson
Sep 20, 2011·Revista de calidad asistencial : organo de la Sociedad Española de Calidad Asistencial·R Fernández UrrusunoV Cuberos Fernández
Dec 20, 2012·International Journal of Hypertension·Mamas TheodorouVasilios Papademetriou
Jun 5, 2013·The Journal of Clinical Hypertension·F Wilford Germino
Aug 13, 2014·Journal of the American Society of Nephrology : JASN·Efrain ReisinMahboob Rahman

❮ Previous
Next ❯

Citations

Oct 20, 2018·Biomédica : revista del Instituto Nacional de Salud·Jorge Enrique Machado-AlbaJuan Daniel Castrillón-Spitia
Sep 24, 2020·Pharmacology Research & Perspectives·Juan-Sebastian Franco, David Vizcaya
Aug 6, 2020·Drugs -- Real World Outcomes·Jorge Enrique Machado-AlbaLuis Fernando Valladales-Restrepo
Sep 6, 2018·Revista de salud pública·Jorge E Machado-AlbaManuel E Machado-Duque

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.